Unlicensed and Off-Label Medication Use in a Neonatal Intensive Care Unit: A Prospective Study

ABSTRACT

The aim of this study is to determine the extent of use of medications that have not been specifically licensed for use in children (unlicensed), or medications whose use is not in accordance with the conditions of their license (off-label), in neonates in a neonatal intensive care unit (NICU). Medications given to 105 neonates were prospectively reviewed every 2 weeks during a 4-month period. The assessment as to whether every medication prescribed was unlicensed or off-label for use in children was based on a number of reference sources. Five hundred and twenty-five series of medications were used, of which 310 (59%) were off-label and 87 (16%) were unlicensed. Ninety-eight neonates (93%) received at least one off-label medication. The major reason for prescribing off-label medications was a deviation from the recommended dosage or age of the patient. The reason for giving unlicensed medications was changes in the formulation of the medication. The use of off-label and unlicensed medications is common in neonates. In view of the gravity and problematic nature of the issue, international consensus is evolving to conduct clinical trials in neonates and infants, with regard to medications already on the market, and new medications.

KEYWORD

Off-label medications - unlicensed medications - neonate - orphan drugs

REFERENCES

• 1 Turner S, Nunn A J, Choonara I. Unlicensed drug uses in children in the UK.  Pediat Perinat Drug Ther . 1997;  1 52-55
• 2 Redmon R B. How children can be respected as ``ends'' yet still be used as subjects in non-therapeutic research.  J Med Ethics . 1986;  12 70-82
• 3 Autret E. European regulatory authorities and pediatric labeling.  Pediatrics . 1999;  104 614-618
• 4 Bonati M, Choonara I, Hoppu K. Closing the gap in drug therapy.  Lancet . 1999;  353 1625
• 5 Gorodisher R. The therapeutic orphan: end of era.  Harefuah . 1998;  135 601-602
• 6 Riordan F A. Use of unlabelled and off-license drugs may be recommended in guidelines.  BMJ . 2000;  320 1210
• 7 Lifshitz M, Gavrilov V, Gorodisher R. Drug therapy in hospitalized children: is the drug license match their daily intake?.  Harefuah . 1999;  137 532-534
• 8 Conroy S, Choonara I, Impicciatore P. Survey of unlicensed and off-label drug use in pediatric wards in European countries: European network for drug investigation in children.  BMJ . 2000;  320 79-82
• 9 Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates.  Arch Dis Child Fetal Neonat Ed . 1999;  80 F142-F145
• 10 Turner S, Longworth A, Nunn A J, Choonara I. Unlicensed and off-label drug use in pediatric wards prospective study.  BMJ . 1998;  316 343-345
• 11 Turner S, Gill A, Nunn T. Use of off-label and unlicensed drugs in pediatric intensive care unit.  Lancet . 1996;  347 549-550
• 12 Avenel S, Bomkratz A, Dassieu G. The incidence of prescriptions without marketing product license in a neonatal intensive care unit.  Arch Pediatr . 2000;  7 143-147
• 13 Abramson J S, Holland M E. Off label use of antimicrobial agents in infants, children and adolescents: a time for action.  Pediatr Infect Dis J . 1998;  17 739-744
• 14 Conroy S. Unliscensed and off label drug use for paediatric patients: optimal dosing schedules with gentamicin are needed for premature neonates.  BMJ . 1998;  317 204-205
• 15 Somberg J C. Pediatric exclusivity and genericizing pharmaceuticals.  Am J Ther . 2001;  8 79-80
• 16 Karst K R. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.  Am Univ Law Rev . 2000;  49 739-772
• 17 Gavrilov V, Lifshitz M, Levy J, Gorodischer R. Unlicensed and off-label medication use in a general pediatric ambulatory hospital unit in Israel.  IMAJ . 2000;  2 595-597
• 18 Physician's Desk Reference. 54th ed. Montvale, NJ: Medical Economics Company 2000
• 19 Israel Drug Compendium. In: York V Azulay R eds. Tel-Aviv: Medcom . 1995
• 20 Medic. In: Bergman SH ed. Herzlia: Shirol Publications . 2000
• 21 Turner S, Nunn A J, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on pediatric wards: a prospective study.  Acta Pediatrica . 1999;  88 965-968
• 22 Muttitt S C, Tierney A J, Finer N N. The dose response of theophylline in the treatment of apnea of prematurity.  J Pediat . 1998;  112 115-121
• 23 Pediatric studies of drugs, Section 111 of the Food and Drug Modernization Act 21, United States Code 355a. 1997; 
• 24 Pediatric patients - regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products: final rule.. Fed Regst . 1998;  63 66631-66672